RIP1–HAT1–SIRT complex identification and targeting in treatment and prevention of cancer

Vincenzo Carafa, Angela Nebbioso, Francesca Cuomo, Dante Rotili, Gilda Cobellis, Paola Bontempo, Alfonso Baldi, Enrico P. Spugnini, Gennaro Citro, Angela Chambery, Rosita Russo, Menotti Ruvo, Paolo Ciana, Luca Maravigna, Jani Shaik, Enrico Radaelli, Pasquale De Antonellis, Domenico Tarantino, Adele Pirolli, Rino RagnoMassimo Zollo, Hendrik G. Stunnenberg, Antonello Mai, Lucia Altucci

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Purpose: Alteration in cell death is a hallmark of cancer. A functional role regulating survival, apoptosis, and necroptosis has been attributed to RIP1/3 complexes. Experimental Design: We have investigated the role of RIP1 and the effects of MC2494 in cell death induction, using different methods as flow cytometry, transcriptome analysis, immunoprecipitation, enzymatic assays, transfections, mutagenesis, and in vivo studies with different mice models. Results: Here, we show that RIP1 is highly expressed in cancer, and we define a novel RIP1/3–SIRT1/2–HAT1/4 complex. Mass spectrometry identified five acetylations in the kinase and death domain of RIP1. The novel characterized pan-SIRT inhibitor, MC2494, increases RIP1 acetylation at two additional sites in the death domain. Mutagenesis of the acetylated lysine decreases RIP1-dependent cell death, suggesting a role for acetylation of the RIP1 complex in cell death modulation. Accordingly, MC2494 displays tumor-selective potential in vitro, in leukemic blasts ex vivo, and in vivo in both xenograft and allograft cancer models. Mechanistically, MC2494 induces bona fide tumor-restricted acetylated RIP1/caspase-8–mediated apoptosis. Excitingly, MC2494 displays tumor-preventive activity by blocking 7,12-dimethylbenz(α)anthracene–induced mammary gland hyperproliferation in vivo. Conclusions: These preventive features might prove useful in patients who may benefit from a recurrence-preventive approach with low toxicity during follow-up phases and in cases of established cancer predisposition. Thus, targeting the newly identified RIP1 complex may represent an attractive novel paradigm in cancer treatment and prevention.

Original languageEnglish
Pages (from-to)2886-2900
Number of pages15
JournalClinical Cancer Research
Issue number12
Publication statusPublished - 15 Jun 2018
Externally publishedYes


Dive into the research topics of 'RIP1–HAT1–SIRT complex identification and targeting in treatment and prevention of cancer'. Together they form a unique fingerprint.

Cite this